NEWS & EVENTS

Catalent today announced that it has signed an agreement with Therachon AG to support development of TA-46, a novel protein addressing achondroplasia, the most common form of short-limbed dwarfism.

Catalent today announced that Christopher Hepler, Group Leader in Biologics Analytical Services at Catalent’s site in Research Triangle Park, North Carolina, will be presenting at the upcoming CASSS Bioassays Symposium.

Catalent today announced that Dr. David Rabuka, Global Head of Research and Development, Chemical Biology, Catalent Biologics, will be presenting at the upcoming Protein And Antibody Engineering Summit.

Catalent Pharma Solutions today announced that Matthew Stober has been appointed to the advisory board of the company’s biologics business.

Catalent today announced that two leading analytical experts from Catalent Biologics will be presenting a workshop on the development and validation of bioassays at the BEBPA U.S. Bioassay Conference.

Catalent today announced that Dr. Christelle Dagoneau, Director of Catalent Biologics in Europe, will be presenting at the upcoming 3rd Annual Biosimilars Summit, to in Berlin on Feb. 23 – 24, 2017.

Catalent today announced that it will be hosting a workshop on the development and delivery of advanced biologics alongside leading experts from Johns Hopkins University, Scripps Research Institute, and UCSF.

Catalent today announced that Mr. Michael Merges, Director of Strategic Growth, Catalent Biologics Analytical Services, will be presenting at the upcoming WCBP Conference in Washington DC, on Jan. 24 – 26, 2017.

Catalent today announced it has signed an agreement with PATH, an international nonprofit organization and a leader in global health innovation, to advance a project funded by its Malaria Vaccine Initiative (MVI).